Peroxiredoxin-6与急性髓系白血病多药耐药发生的相关性  

The correlation of Peroxiredoxin-6 with the development of multidrug resistance in acute myeloid leukemia

作　　者：杨海玉[1] 刘勇[2] 柯波[3] 吴晓霞[4] 

机构地区：[1]江西省人民医院临床医学研究所,南昌330006 [2]江西省人民医院病理科,南昌330006 [3]江西省人民医院血液内科,南昌330006 [4]江西省人民医院体检科,南昌330006

出　　处：《临床与病理杂志》2016年第11期1800-1804,共5页Journal of Clinical and Pathological Research

基　　金：江西省卫生厅科技计划项目(20161014)~~

摘　　要：目的:探讨Peroxiredoxin-6与急性髓系白血病(acute myeloid leukemia,AML)多药耐药发生的相关性。方法:获取16例AML病人骨髓标本,根据化疗不同疗效分为多药耐药组(7例)和化疗敏感组(9例),采用双向电泳和质谱分析检测两组之间差异表达的蛋白质,之后采用RT-PCR进一步验证差异蛋白表达结果。结果:蛋白质组学实验结果显示,两组之间差异显著的蛋白点共29个,其中第17号蛋白点经鉴定为抗氧化酶Peroxiredoxin-6。RT-PCR结果证实,与化疗敏感组相比,多药耐药组中Peroxiredoxin-6表达水平明显增高(P<0.001)。结论:Peroxiredoxin-6在AML多药耐药病人骨髓细胞中高表达,提示Peroxiredoxin-6可能与AML多药耐药发生相关。Objective： To study the correlation of Peroxiredoxin-6 with the development of multidrug resistance in acute myeloid leukemia （AML）. Methods： Bone marrow samples were derived from 16 AML patients, which were divided into multidrug resistance group （n=7） and chemo-responsive group （n=9）. With two-dimensional electrophoresis and mass spectrographic analysis, we detected the differentially expression of proteins in the bone marrow between two groups. After that, the differentially expressed protein level was further demonstrated by RT-PCR. Results： A total of 29 protein spots with significant difference were found and the protein of No.17 was identified as Peroxiredoxin-6, a kind of antioxidant enzyme. Compared with chemo-responsive group, the expression of Peroxiredoxin-6 was significantly increased in multidrug resistance group （P〈0.001）. Conclusion： Peroxiredoxin-6 is over-expressed in bone marrow cells of AML multi-resistant patient and it may be associated with the occurrence of AML multi-resistance.

关 键 词：急性髓系白血病 多药耐药 Peroxiredoxin-6 蛋白质组学 

分 类 号：R733.71[医药卫生—肿瘤]